Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQ: CRVS · Real-Time Price · USD
3.630
-0.030 (-0.82%)
At close: Apr 25, 2025, 4:00 PM
3.750
+0.120 (3.31%)
Pre-market: Apr 28, 2025, 7:33 AM EDT
Corvus Pharmaceuticals Employees
Corvus Pharmaceuticals had 31 employees as of December 31, 2024. The number of employees increased by 3 or 10.71% compared to the previous year.
Employees
31
Change (1Y)
3
Growth (1Y)
10.71%
Revenue / Employee
n/a
Profits / Employee
-$2,009,452
Market Cap
247.33M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
CRVS News
- 4 days ago - Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025 - GlobeNewsWire
- 18 days ago - Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors - GlobeNewsWire
- 4 weeks ago - Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials - Seeking Alpha
- 4 weeks ago - Corvus Pharmaceuticals: Now At Cruising Altitude - Seeking Alpha
- 4 weeks ago - Corvus Pharmaceuticals, Inc. (CRVS) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 5 weeks ago - Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma - GlobeNewsWire
- 5 weeks ago - Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - GlobeNewsWire